(TWST) Twist Bioscience - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 2.866m USD | Total Return: 10.2% in 12m

Stock Synthetic DNA, Gene Synthesis, Oligos, NGS Tools, RNA Controls
Total Rating 34
Risk 39
Buy Signal -0.71
Diagnostics & Research +11.3
Biotechnology -7.1
Market Cap: 2,866m
Avg Trading Vol: 45.7M USD
ATR: 7.06%
Peers RS (IBD): 58.8
Risk 5d forecast
Volatility68.1%
Rel. Tail Risk-6.30%
Reward TTM
Sharpe Ratio0.37
Alpha-19.34
Character TTM
Beta2.258
Beta Downside1.751
Drawdowns 3y
Max DD58.97%
CAGR/Max DD0.78
EPS (Earnings per Share) EPS (Earnings per Share) of TWST over the last years for every Quarter: "2021-03": -0.78, "2021-06": -0.78, "2021-09": -0.84, "2021-12": -0.91, "2022-03": -1.13, "2022-06": -1.08, "2022-09": -0.91, "2022-12": -0.74, "2023-03": -1.04, "2023-06": -0.78, "2023-09": -0.81, "2023-12": -0.75, "2024-03": -0.79, "2024-06": -1.47, "2024-09": -0.59, "2024-12": -0.53, "2025-03": -0.66, "2025-06": -0.47, "2025-09": -0.45, "2025-12": -0.5, "2026-03": 0,
EPS CAGR: 37.77%
EPS Trend: 71.8%
Last SUE: 1.75
Qual. Beats: 1
Revenue Revenue of TWST over the last years for every Quarter: 2021-03: 31.204, 2021-06: 35.018, 2021-09: 37.951, 2021-12: 42.018, 2022-03: 48.127, 2022-06: 56.113, 2022-09: 57.306, 2022-12: 54.243, 2023-03: 60.18, 2023-06: 63.74, 2023-09: 66.946, 2023-12: 71.498, 2024-03: 75.302, 2024-06: 81.464, 2024-09: 84.71, 2024-12: 88.713, 2025-03: 92.793, 2025-06: 96.057, 2025-09: 99.009, 2025-12: 103.698, 2026-03: null,
Rev. CAGR: 22.72%
Rev. Trend: 98.9%
Last SUE: 1.04
Qual. Beats: 2
Risks
Technicals: volatile
Description: TWST Twist Bioscience March 04, 2026

Twist Bioscience Corporation manufactures and sells synthetic DNA products. These products include synthetic genes, oligo pools, and immunoglobulin G proteins. The companys offerings support various applications in therapeutics, diagnostics, chemicals/materials, food/agriculture, and academic research.

The biotechnology sector, where Twist Bioscience operates, is characterized by significant research and development investment aimed at discovering and developing new biological products and technologies. Twist Biosciences business model focuses on providing foundational synthetic biology tools to other companies and research institutions, rather than developing end-user therapeutic drugs itself.

Twist Bioscience also provides next-generation sequencing (NGS) tools, including library preparation kits and exome kits, and methylation detection kits. They also offer synthetic viral RNA reference sequences for SARS-CoV-2, monkeypox, and other respiratory viruses, which are crucial for assay development and research.

The company also develops precision DNA libraries for antibody engineering and optimization solutions. For further details on TWSTs financial performance and market position, consider exploring ValueRay.

Headlines to Watch Out For
  • Synthetic gene and oligo demand drives revenue growth
  • NGS tools adoption expands market share
  • Biopharma partnerships accelerate drug discovery
  • Data storage applications offer long-term potential
  • Research and development expenses impact profitability
Piotroski VR‑10 (Strict, 0-10) 2.5
Net Income: -76.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.14 > 0.02 and ΔFCF/TA -2.35 > 1.0
NWC/Revenue: 57.06% < 20% (prev 83.49%; Δ -26.42% < -1%)
CFO/TA -0.08 > 3% & CFO -51.0m > Net Income -76.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.78 > 1.5 & < 3
Outstanding Shares: last quarter (61.1m) vs 12m ago 3.24% < -2%
Gross Margin: 51.62% > 18% (prev 0.45%; Δ 5.12k% > 0.5%)
Asset Turnover: 62.82% > 50% (prev 54.26%; Δ 8.56% > 0%)
Interest Coverage Ratio: -528.4 > 6 (EBITDA TTM -51.2m / Interest Expense TTM 143k)
Altman Z'' -13.21
A: 0.35 (Total Current Assets 303.9m - Total Current Liabilities 80.4m) / Total Assets 638.1m
B: -2.12 (Retained Earnings -1.35b / Total Assets 638.1m)
C: -0.12 (EBIT TTM -75.6m / Avg Total Assets 623.3m)
D: -7.42 (Book Value of Equity -1.35b / Total Liabilities 182.0m)
Altman-Z'' Score: -13.21 = D
Beneish M -2.75
DSRI: 1.07 (Receivables 50.1m/39.3m, Revenue 391.6m/330.2m)
GMI: 0.86 (GM 51.62% / 44.59%)
AQI: 1.41 (AQ_t 0.25 / AQ_t-1 0.17)
SGI: 1.19 (Revenue 391.6m / 330.2m)
TATA: -0.04 (NI -76.6m - CFO -51.0m) / TA 638.1m)
Beneish M-Score: -2.75 (Cap -4..+1) = A
What is the price of TWST shares? As of March 31, 2026, the stock is trading at USD 43.26 with a total of 1,077,097 shares traded.
Over the past week, the price has changed by -2.79%, over one month by -7.80%, over three months by +34.56% and over the past year by +10.19%.
Is TWST a buy, sell or hold? Twist Bioscience has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy TWST.
  • StrongBuy: 6
  • Buy: 3
  • Hold: 2
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the TWST price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 49.9 15.3%
Analysts Target Price 49.9 15.3%
TWST Fundamental Data Overview March 28, 2026
P/S = 7.3203
P/B = 5.6594
Revenue TTM = 391.6m USD
EBIT TTM = -75.6m USD
EBITDA TTM = -51.2m USD
Long Term Debt = 98.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 12.2m USD (from shortTermDebt, last quarter)
Debt = 183.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 35.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.85b USD (2.87b + Debt 183.9m - CCE 197.9m)
Interest Coverage Ratio = -528.4 (Ebit TTM -75.6m / Interest Expense TTM 143k)
EV/FCF = -32.89x (Enterprise Value 2.85b / FCF TTM -86.7m)
FCF Yield = -3.04% (FCF TTM -86.7m / Enterprise Value 2.85b)
FCF Margin = -22.15% (FCF TTM -86.7m / Revenue TTM 391.6m)
Net Margin = -19.56% (Net Income TTM -76.6m / Revenue TTM 391.6m)
Gross Margin = 51.62% ((Revenue TTM 391.6m - Cost of Revenue TTM 189.4m) / Revenue TTM)
Gross Margin QoQ = 52.05% (prev 51.35%)
Tobins Q-Ratio = 4.47 (Enterprise Value 2.85b / Total Assets 638.1m)
Interest Expense / Debt = 0.08% (Interest Expense 143k / Debt 183.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -59.7m (EBIT -75.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.78 (Total Current Assets 303.9m / Total Current Liabilities 80.4m)
Debt / Equity = 0.40 (Debt 183.9m / totalStockholderEquity, last quarter 456.1m)
 Debt / EBITDA = -0.69 (negative EBITDA) (Net Debt 35.3m / EBITDA -51.2m)
 Debt / FCF = -0.41 (negative FCF - burning cash) (Net Debt 35.3m / FCF TTM -86.7m)
 Total Stockholder Equity = 461.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.29% (Net Income -76.6m / Total Assets 638.1m)
RoE = -16.58% (Net Income TTM -76.6m / Total Stockholder Equity 461.8m)
RoCE = -13.50% (EBIT -75.6m / Capital Employed (Equity 461.8m + L.T.Debt 98.0m))
 RoIC = -12.93% (negative operating profit) (NOPAT -59.7m / Invested Capital 461.8m)
 WACC = 13.08% (E(2.87b)/V(3.05b) * Re(13.92%) + D(183.9m)/V(3.05b) * Rd(0.08%) * (1-Tc(0.21)))
Discount Rate = 13.92% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.07%
 [DCF] Fair Price = unknown (Cash Flow -86.7m)
 EPS Correlation: 71.84 | EPS CAGR: 37.77% | SUE: 1.75 | # QB: 1
Revenue Correlation: 98.93 | Revenue CAGR: 22.72% | SUE: 1.04 | # QB: 2
EPS next Quarter (2026-06-30): EPS=-0.49 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-09-30): EPS=-1.97 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+6.9% | Growth Revenue=+16.6%
EPS next Year (2027-09-30): EPS=-1.89 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+4.3% | Growth Revenue=+14.8%
Additional Sources for TWST Stock Fund Manager Positions: Dataroma · Stockcircle